## CLAIMS

1. A tetrahydroquinoline derivative represented by the following formula (I) or pharmacologically acceptable salts thereof:

wherein  $R^1$  represents a nitro group or a cyano group; X represents CH or O, provided that when X is CH, the dashed line represents a double bond;

10 m represents 0 or 1;

5

Y represents an alkylene group having 1 - 5 carbon atoms which may be substituted by a substituent selected from the group consisting of an alkyl group having 1 - 5 carbon atoms and a cycloalkyl group having 3 - 7 carbon atoms;

15 R<sup>2</sup> represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms or an aralkyl group having 7 - 9 carbon atoms;

Z represents -B-O-Q

[wherein B represents an alkylene group having 1 - 5 carbon
atoms which may be substituted by a substituent selected
from the group consisting of an alkyl group having 1 - 5
carbon atoms and a cycloalkyl group having 3 - 7 carbon

atoms; Q is a hydrogen atom, an alkyl group having 1-5 carbon atoms or a cycloalkyl group having 3-7 carbon atoms which may be substituted by a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group and an alkoxy group having 1-5 carbon atoms, or an aryl group, a heteroaryl group or an aralkyl group having 7-9 carbon atoms which may have a substituent  $R^3$ ,

R<sup>3</sup> represents an alkyl group having

5

1 - 5 carbon atoms which may be substituted by a fluorine 10 atom, a halogen atom, an aryl group, a heteroaryl group, a nitro group, a cyano group, -A-R4 {wherein A represents  $-CO_{2}$ ,  $-CO_{2}$ ,  $-COS_{2}$ ,  $-CONR_{3}$ ,  $-O_{2}$ ,  $-OCO_{2}$ ,  $-S_{2}$ ,  $-S_{3}$ ,  $-S_{2}$ -SO-,  $-SO_2-$ ,  $-NR^5-$ ,  $-NR^5CO-$ ,  $-NR^5SO_2-$ ,  $-NR^5CONH-$ ,  $-NR^5CSNH-$  or -NR<sup>5</sup>COO- (wherein R<sup>5</sup> represents a hydrogen atom, an alkyl 15 group having 1 - 5 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms or an aralkyl group having 7 - 9 carbon atoms), R4 is a hydrogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a 20 cycloalkyl group having 3 - 7 carbon atoms, a halogen atom, or an aryl group or a heteroaryl group which may be substituted by R<sup>6</sup> (wherein R<sup>6</sup> represents an alkyl group having 1 - 5 carbon atoms, an alkoxy group having 1 - 5 carbon atoms or a halogen atom), provided that when A is -NR5- or -CONR5-, R4 and R5 may, together with the nitrogen 25 atom to which they are bonded, form pyrrolidine or piperidine)}, or -A'-(CH<sub>2</sub>)<sub>n</sub>-R<sup>4'</sup> {wherein A' represents a single bond,  $-CO_2$ ,  $-CO_2$ -,  $-COS_2$ -,  $-CONR_3$ -,  $-O_2$ -,  $-OCO_2$ -,  $-OSO_3$ -,

-S-, -SCO-, -SO-, -SO<sub>2</sub>-, -NR<sup>5</sup>'-, -NR<sup>5</sup>'CO-, -NR<sup>5</sup>'SO<sub>2</sub>-, -NR<sup>5</sup>'CONH-, -NR<sup>5</sup>'CSNH- or -NR<sup>5</sup>'COO- (wherein R<sup>5</sup>' represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms or an aralkyl group having 7 - 9 carbon atoms), n represents an integer of 1 or 2, R4' represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a cycloalkyl group having 3 - 7 carbon atoms, a halogen atom, a hydroxyl group, a cyano group, an alkoxy group having 1 - 5 carbon atoms, an 10 alkylacyloxy group having 2 - 5 carbon atoms, an alkoxycarbonyl group having 2 - 5 carbon atoms, an aryl group or a heteroaryl group which may be substituted by R6' (wherein R6' represents an alkyl group having 1 - 5 carbon 15 atoms, an alkoxy group having 1 - 5 carbon atoms or a halogen atom), or  $-NR^{7'}R^{8'}$  (wherein  $R^{7'}$  and  $R^{8'}$  each independently have the same meaning as the aforementioned R<sup>5'</sup>, provided that R<sup>7'</sup> and R<sup>8'</sup> may, together with the nitrogen atom to which they are bonded, form pyrrolidine or piperidine), provided that when A' is -NR5'- or -CONR5'-, R4' 20 and  $R^{5}$  may, together with the  $-N-(CH_2)_n-$  to which they are bonded, form pyrrolidine or piperidine}], or alternatively Z represents  $-(CH_2)_r-W$ [wherein r represents an integer of 0 - 2, W represents 25 a phenyl group having substituent R' at p-position, a naphthyl group which may have substituent R10 or a heteroaryl group which may be substituted by 1 - 3

independent R11's (wherein R9, R10 and R11 independently have

the same meaning as the aforementioned R3)].

5

- 2. The tetrahydroquinoline derivative according to claim 1, where Y is  $-CH(CH_3)-CH_2-$  or  $-C(CH_3)_2-CH_2-$ , X is CH, m is 0,  $R^2$  is a hydrogen atom and Z is  $-CH_2-O-Q$  (wherein Q represents an alkyl group having 1 5 carbon atoms) or pharmacologically acceptable salts thereof.
- 3. The tetrahydroquinoline derivative according to claim 1, where Y is  $-CH(CH_3)-CH_2-$  or  $-C(CH_3)_2-CH_2-$ , m is 0,  $R^2$  is a hydrogen atom and Z is -W [wherein W is a
- heteroaryl group which may be substituted by 1 3 independent R<sup>11</sup>'s or a phenyl group having substituent R<sup>9</sup> at p-position {wherein R<sup>11</sup> and R<sup>9</sup> independently represent a halogen atom, an alkyl group having 1 5 carbon atoms which may be substituted by a fluorine atom, a nitro group,
- a cyano group,  $-A-R^4$  (wherein A is -CO-,  $-CO_2-$ , -O-, -NHCO- or -NHCONH-, and  $R^4$  is a hydrogen atom or an alkyl group having 1 5 carbon atoms which may be substituted by a fluorine atom) or  $-A'-(CH_2)_n-R^{4'}$  (wherein A' is -CO-,  $-CO_2-$ , -O-, -NHCO- or -NHCONH-,  $R^{4'}$  is a hydrogen atom, an alkyl
- group having 1 5 carbon atoms which may be substituted by a fluorine atom, a hydroxyl group, a halogen atom or an alkoxy group having 1 5 carbon atoms, and n is an integer of 1 or 2)}] or pharmacologically acceptable salts thereof.
- 4. The tetrahydroquinoline derivative according to

  25 claim 3, where Z is a phenyl group having substituent R° at
  p-position or a heteroaryl group having substituent R¹¹

  {wherein R° and R¹¹ independently represent a halogen atom,

  -O-R⁴ or -NHCO-R⁴ (wherein R⁴ represents a hydrogen atom or

an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom)} or pharmacologically acceptable salts thereof. The tetrahydroquinoline derivative according to claim 3, where Z is a phenyl group having substituent R9 at 5 p-position or a heteroaryl group having substituent R11 {wherein R<sup>9</sup> and R<sup>11</sup> represent -NHCO-R<sup>4</sup> (wherein R<sup>4</sup> represents a hydrogen atom or an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom)} or 10 pharmacologically acceptable salts thereof. 6. A pharmaceutical comprising the tetrahydroquinoline derivative or pharmacologically acceptable salts thereof according to any one of claims 1 to 5 as an active ingredient. The pharmaceutical according to claim 6, which is an 15 7. androgen receptor agonist. The pharmaceutical according to claim 7, which can 8. be used in the prevention or treatment of wasting disease or osteoporosis. The pharmaceutical according to claim 7, which can 20 9. be used in the prevention or treatment of a disease selected from the group consisting of male hypogonadism, male sexual dysfunction, abnormal sex differentiation, male delayed puberty, cancer in female genital organ, breast cancer, mastopathy, endometriosis and female sexual 25 dysfunction. The pharmaceutical according to claim 7, which can 10. be used in the prevention or treatment of hematopoietic

dysfunction and diseases related thereto.

- 11. A method of preventing or treating wasting disease or osteoporosis, which comprises administering to a mammal in need of such prevention or treatment, the
- tetrahydroquinoline derivative or pharmacologically acceptable salts thereof according to any one of claims 1 to 5 in an amount effective to prevent or treat those diseases.
- 12. A method of preventing or treating a disease

  10 selected from the group consisting of male hypogonadism,
  male sexual dysfunction, abnormal sex differentiation, male
  delayed puberty, cancer in female genital organ, breast
  cancer, mastopathy, endometriosis and female sexual
  dysfunction, which comprises administering to a mammal in

  15 need of such prevention or treatment, the
  tetrahydroquinoline derivative or pharmacologically
  - tetrahydroquinoline derivative or pharmacologically acceptable salts thereof according to any one of claims 1 to 5 in an amount effective to prevent or treat those diseases.
- 20 13. A method of preventing or treating hematopoietic dysfunction or diseases related thereto, which comprises administering to a mammal in need of such prevention or treatment, the tetrahydroquinoline derivative or pharmacologically acceptable salts thereof according to any one of claims 1 to 5 in an amount effective to prevent or

treat those diseases.